Full-Time
Posted on 5/13/2025
Clinical-stage biotech developing immunotherapies
$80k - $100k/yr
North Bethesda, MD, USA
In Person
Relocation assistance available for eligible candidates.
Arcellx is a clinical-stage biotechnology company that develops immunotherapies for cell therapy. Its work centers on engineered immune cell treatments designed to fight diseases, with a focus on developing, testing, and eventually commercializing these products. The company’s products work by modifying a patient’s immune cells to recognize and attack diseased cells, then using manufacturing and regulatory steps to bring these therapies to healthcare providers and patients. Arcellx differentiates itself through its proprietary cell-therapy platforms and its emphasis on partnerships, licensing deals, and collaboration with research institutions to advance its products. Its goal is to address unmet medical needs by delivering safe and effective cell-based treatments that can be used in clinical care.
Company Size
201-500
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance
RTW Biotech Opportunities reports February 2026 NAV of $2.41 per share. RTW Biotech Opportunities Ltd (LON:RTW) has announced that its monthly factsheet and commentary as at 28 February 2026. The Company's unaudited net asset value attributable to its ordinary shares as at 28 February 2026 was US$2.41 per share, an increase of +1.7% from the previous month vs +8.3% for the Nasdaq Biotech Index and -0.2% for the Russell 2000 Biotech Index. The Company has delivered +13.6% annualised NAV per ordinary share performance since launch in October 2019. Top 10 Positions Top YTD Contributors and Detractors Note: % NAV as at period end based on economic exposure. SECTOR UPDATE Biotechnology indices outperformed broader equity markets in February and are outperforming year-to-date. The move appears to reflect a rotation away from mega-cap growth and AI-exposed tech names in favour of a more diversified group of sectors including healthcare. Furthermore, declining long term yields supported biotech companies, given their long-duration cash flow profile. Together, these dynamics have begun to re-engage generalist investors who had remained underweight in the space for the past several years. Capital markets activity has remained constructive. Year-to-date, 46 biotech transactions totalling more than $8 billion have been completed, including six IPOs. Approximately two thirds of IPOs year-to-date are trading above offer price, a marked improvement versus early 2025, when issuance was more muted and aftermarket performance less durable. The tentative reopening of the IPO window and improved follow-on performance reflect a gradual normalisation of risk appetite and improving institutional participation. M&A activity also remained robust in February, with two announced transactions: Eli Lilly's acquisition of private RNA therapeutics company Orna Therapeutics for up to $2.4 billion and Gilead's $7.8 billion acquisition of Arcellx, a post-Phase 2 oncology company. Year-to-date, five acquisitions totalling up to $14 billion have been announced. The Arcellx transaction reinforces continued large-cap appetite for validated clinical-stage assets. The sustained pace of deal activity underscores the need for pipeline replenishment across large biopharma with impending material patent cliffs. PERFORMANCE UPDATE Relative underperformance during the month was concentrated in its commercial-stage therapeutics holdings, reflecting mark-to-market pressure rather than evidence of permanent impairment. Winter prescription dynamics, including annual copay resets and periods of severe weather, weighed on prescription volumes across parts of the portfolio. However, DirectorsTalk Interviews believe this seasonal softness was consistent with prior years and does not alter the underlying demand trajectory. DirectorsTalk Interviews remain optimistic on its commercial portfolio, where launch trajectories and underlying fundamentals continue to progress favourably despite near-term volatility. Within its clinical portfolio, DirectorsTalk Interviews maintain a robust catalyst calendar for 2026, with multiple value-inflecting events ahead. DirectorsTalk Interviews believe this positions the portfolio well to benefit from continued strategic activity and improving risk appetite across development-stage biotechnology. RTW Biotech Opportunities Ltd is an investment fund focused on identifying transformative assets across the life sciences sector. * Written by: Amilia Stone RTW Biotech Opportunities Ltd reported an unaudited NAV of $2.41 per share as of 28 February 2026, up 1.7% for the month. Biotech equities outperformed broader markets amid sector rotation and improved capital markets activity. As at 31 January 2026, RTW Biotech Opportunities Ltd recorded an unaudited NAV of US$2.37 per share, reflecting a 3.6% monthly decline. RTW Biotech Opportunities Ltd announces that Boston Scientific Corporation has agreed to acquire Penumbra, Inc., a public portfolio company, in a transaction valued at $14.5 billion.
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion, expanding their cell therapy development collaboration that started in 2022.
Gilead Sciences moves to acquire Arcellx in USD 7.8B deal to fully harness anito-cel potential. 23 February 2026 / 0 Comments Gilead Sciences today announced a definitive agreement to acquire Arcellx in a transaction valued at approximately USD 7.8 billion, marking a major step in Gilead's expansion in next-generation cell therapy. Under the terms of the agreement, Gilead will acquire all outstanding shares of Arcellx not already owned through a tender offer at USD 115 per share in cash plus one contingent value right (CVR) that could deliver an additional USD 5 per share if certain global net sales targets for anito-cel are met through 2029. The boards of both companies have approved the deal, which is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. The acquisition builds on a 2022 collaboration between Gilead's Kite unit and Arcellx to co-develop anito-cel (anitocabtagene autoleucel), an investigational BCMA-directed CAR T-cell therapy for adults with relapsed or refractory multiple myeloma. Anito-cel has previously shown promising deep and durable responses in clinical studies and its Biologics License Application (BLA) has been accepted by the U.S. Food and Drug Administration with a PDUFA target action date set for December 23, 2026. Gilead's Chairman and CEO Daniel O'Day said the agreement reflects the company's strong conviction in anito-cel's potential to provide long-term benefit to patients and to become a foundational therapy for multiple myeloma, potentially extending into earlier lines of treatment. He emphasized that owning the therapy outright will accelerate development and commercialization while eliminating profit-sharing and future royalties. Beyond anito-cel, Arcellx brings a proprietary D-Domain CAR technology platform with enhanced target binding that Gilead plans to leverage for future cell therapy and bispecific approaches. Arcellx CEO Rami Elghandour described the partnership with Gilead as enabling broader access and scale for patients and clinicians. Pending closing, Gilead currently holds roughly 11.5% of Arcellx stock. If the tender offer is successful, Gilead will complete the acquisition through a second step merger on the same terms. Company filings note that, upon U.S. regulatory approval of anito-cel, the transaction is expected to be accretive to Gilead's earnings per share beginning in 2028.
Perceptive Advisors sold 1,002,282 shares of Arcellx during the fourth quarter, with an estimated transaction value of $79.96 million based on quarterly average pricing, according to a 17 February SEC filing. The quarter-end position value declined by $107.06 million, reflecting both share sales and price movements. The sale follows a sharp drop in Arcellx shares after Kelonia presented three-patient data for its in vivo CAR-T approach in November, which sent Arcellx down roughly 17% in a single session. The rival technology could eliminate complex manufacturing steps required for traditional CAR-T therapies. Arcellx's anito-cel is in Phase 3 trials for multiple myeloma in partnership with Gilead's Kite unit. Shares traded at $70.20 on 17 February, up 9% over the past year but still affected by November's sell-off.
Arcellx director David Charles Lubner sold 6,000 shares of the biotechnology company for approximately $450,000 on 20 January, according to an SEC Form 4 filing. The transaction, executed under a Rule 10b5-1 prearranged plan, reduced Lubner's direct holdings by 21.69% from 27,659 to 21,659 shares. The clinical-stage biotechnology company, which specialises in immunotherapies for cancer, currently has a market capitalisation of $3.95 billion. Arcellx operates with negative operating income but has stated it has sufficient funding through 2028. The company recently advanced its multiple myeloma treatment to phase two development. Despite this progress, Arcellx's stock fell approximately 15% in 2025. The company has been publicly traded for about four years.